Cargando…

Case Report: Respiratory paralysis associated with polymyxin B therapy

Polymyxin B (PMB) and colistin are bactericidal polypeptide antibiotics discovered in 1947 and 1949 for the treatment of gram-negative bacterial infections. Polymyxin was used clinically in the 1950s, but it was gradually replaced by other antibiotics in the 1980s because of its high nephrotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Yachan, Chu, Yanqi, Wu, You, Huang, Ying, Wang, Chunmei, Jiang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465242/ https://www.ncbi.nlm.nih.gov/pubmed/36105193 http://dx.doi.org/10.3389/fphar.2022.963140

Ejemplares similares

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation
por: Zou, Dongna, et al.
Publicado: (2021)

Respiratory Muscle Paralysis Associated With Colistin, Polymyxin B, and Muscle Relaxants Drugs: A Case Report
por: Myint, Thein, et al.
Publicado: (2016)

Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?
por: Lu, Cuicui, et al.
Publicado: (2020)

Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance
por: Xu, Caifang, et al.
Publicado: (2022)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Polymyxin B in Patients With Renal Impairment: Is It Necessary to Adjust Dose?
por: Nie, Ruifang, et al.
Publicado: (2022)

Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study
por: Tran, Thien B., et al.
Publicado: (2018)

PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo
por: Chauzy, Alexia, et al.
Publicado: (2022)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
por: Liang, Danhong, et al.
Publicado: (2023)

Visualizing the Potential Impairment of Polymyxin B to Central Nervous System Through MR Susceptibility-Weighted Imaging
por: Zhang, Ni, et al.
Publicado: (2021)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia
por: Zeng, Huihui, et al.
Publicado: (2021)

Use of polymyxin B with different administration methods in the critically ill patients with ventilation associated pneumonia: a single-center experience
por: Shi, Rupeng, et al.
Publicado: (2023)

Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa
por: Lin, Yu-Wei, et al.
Publicado: (2019)

Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections
por: Wu, Xiao-Li, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children
por: Jia, Xuedong, et al.
Publicado: (2022)

Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study
por: Wu, Zhenping, et al.
Publicado: (2023)

Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study
por: Cai, Xiao-Jun, et al.
Publicado: (2022)

A cyclic adenosine monophosphate response element-binding protein inhibitor enhances the antibacterial activity of polymyxin B by inhibiting the ATP hydrolyzation activity of CrrB
por: Huang, Wei, et al.
Publicado: (2022)

Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae
por: Diep, John K., et al.
Publicado: (2018)

Research Trends and Collaboration Patterns on Polymyxin Resistance: A Bibliometric Analysis (2010–2019)
por: Quincho-Lopez, Alvaro, et al.
Publicado: (2021)

Polymyxin B-induced rhabdomyolysis: A case report
por: Ni, Ming, et al.
Publicado: (2020)

Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wang, Peile, et al.
Publicado: (2020)

In silico genome-scale metabolic modeling and in vitro static time-kill studies of exogenous metabolites alone and with polymyxin B against Klebsiella pneumoniae
por: Chung, Wan Yean, et al.
Publicado: (2022)

Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant Klebsiella pneumoniae Infections a Retrospective Study
por: Fang, Jie, et al.
Publicado: (2021)

Correlation between the drug concentration of polymyxin B and polymyxin B‐associated acute kidney injury in critically ill patients: A prospective study
por: Xu, Ying, et al.
Publicado: (2022)

Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients
por: Deng, Yang, et al.
Publicado: (2022)

Respiratory arrest associated with polymyxin B in a lung transplant patient
por: Chen, Wen-Hui, et al.
Publicado: (2020)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

Editorial: Case reports in respiratory pharmacology 2022
por: Zdziarski, Przemyslaw, et al.
Publicado: (2023)

Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID‐19
por: Ishiwari, Mayuko, et al.
Publicado: (2020)

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy
por: Li, Lu, et al.
Publicado: (2020)

Transcriptional responses of Burkholderia cenocepacia to polymyxin B in isogenic strains with diverse polymyxin B resistance phenotypes
por: Loutet, Slade A, et al.
Publicado: (2011)

Case Report: Diffuse Large B Cell Lymphoma After Cardiac Transplantation due to Anthracycline-Induced Dilated Cardiomyopathy in Pediatric Acute Lymphoblastic Leukemia
por: Xin, Ning, et al.
Publicado: (2022)

Polymyxin B and fusidic acid, a novel potent synergistic combination against Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
por: Chen, Shuying, et al.
Publicado: (2023)

Respiratory Paralysis in Poliomyelitis
por: Napier, William, et al.
Publicado: (1948)

Polymyxin B-Induced Skin Hyperpigmentation
por: Wen, Xueke, et al.
Publicado: (2020)

Structure-Function Studies of Polymyxin B Lipononapeptides
por: Gallardo-Godoy, Alejandra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i8iiov35465t8ts1betnkm5b2c